Contraception Archives - Endocrinology Advisor

Contraception

NDA for Twirla Contraceptive Patch Resubmitted to FDA

Agile Therapeutics has resubmitted to the Food and Drug Administration (FDA) the New Drug Application (NDA) for its product, Twirla, an investigational low-dose combined hormonal contraceptive patch (AG200-15). Based on the results from a comparative wear study, the resubmitted NDA will address the FDA’s questions on in vivo adhesion, additional information on the Company’s manufacturing…

Next post in Bone Metabolism